Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Italy's urgent pro-industry talks face patient wait

This article was originally published in Clinica

Executive Summary

Despite the urgency voiced by Italy’s austerity-beleaguered medtech industry following the elections (, 28 February 2013), the sector must wait at least another three weeks for parliamentarians to be anywhere near ready to discuss how best to help the country through its economic crisis, including completing the country’s austerity measures. Formalities around the registration of members of the Chamber of Deputies and the Senate will kick off next week, with the first serious talks between the political groups and alliances that emerge due to take place from 15 March, according to a parliamentary calendar described in national reports. These groupings and their leaders are not expected to be in place before 20 March, and the election of the new prime minister is likely to take place in the last week of March. “The range of possible scenarios is wide open and too hard to predict,” according to healthcare news daily Quotidianosanità.

You may also be interested in...

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning

Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.

Horizon's Teprotumumab Breezes Through US FDA Adcom, But Safety Questions Remain

Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts